Company intelligence / Profile preview

ZZP

Ownership: Private
Development stage: Commercial

Overview

ZZ Biotech’s lead drug candidate, 3K3A-APC, is a recombinant variant of human activated protein C designed to maximize cytoprotective/anti-inflammatory effects while minimizing anticoagulant risk. It has been granted FDA Fast Track status for acute ischemic stroke. Clinical results are not detailed publicly but the company remains active in development.

Therapeutic areas: DermatologyCardiovascularNeurology
Modalities: Recombinant proteinProtein (specifically, genetically engineered serine protease)Biologic
Industry: Biotech

Partnerships

Laureate Pharma—contract manufacturing partnership for production of activated protein C variants.

Beyond the preview

Go deeper on ZZP.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZZP.

Explore the full profile